Abstract 1707P
Background
Rising cancer drug prices pose a challenge for patients and healthcare systems in the US. Whilst prices are routinely assigned to a drug’s original indication receiving US Food and Drug Administration (FDA) approval, the influence of supplemental indication approvals on prices remains uncertain. This study identifies and quantifies factors associated with cancer drug prices, distinctly analyzing original and supplemental indications.
Methods
Clinical trial evidence supporting each indication’s FDA approval was collected from the Drugs@FDA database (2003-2022). Disease incidence and disability-adjusted life years (DALYs) were obtained from the Global Burden of Disease study. Indication-specific monthly treatment costs were calculated for patients covered under Medicare Part B and D. The association between log-prices and collected variables was assessed in univariate regression analyses.
Results
We identified 145 drugs approved across 373 cancer indications. Drugs were priced at $24,444 per month on average (median $16,013; IQR 14,648 to 22,348). For original indications, prices were only weakly correlated to improvements in overall survival (β=0.28, 95%CI 0.02 to 0.54, p=0.037) and progression-free survival (β=0.16, 95%CI 0.07 to 0.25, p=0.001). Original indications’ prices were: (1) negatively associated with disease incidence (β=-0.21, 95%CI -0.28 to -0.13, p<0.001) and prevalence; (2) positively correlated for first-in-class drugs (26%, 95%CI -1 to 60, p=0.057), gene & cell therapies (176%, 95%CI 79 to 324, p<0.001), hematologic cancers (52%, 95%CI 28 to 106, p<0.001), and severe diseases with substantial unmet needs (6% per DALY, 95%CI 3 to 8, p<0.001); and (3) negatively correlated to indications with randomized controlled phase III trials. Prices were only poorly associated with supplemental indications’ efficacy, clinical evidence, and epidemiology.
Conclusions
Cancer drug prices are set based on the original indication’s characteristics, thereby omitting the value of supplemental indications. Indication-specific pricing, coverage, and reimbursement policies considering each indication’s safety, efficacy, innovativeness, and unmet needs are necessary to align a drug’s value and price.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1737P - Use of the predictive risk model LungFlagTM for lung cancer screening in screening in a Spanish reference center: A cost-effectiveness analysis
Presenter: Maria Eugenia Olmedo Garcia
Session: Poster session 23
1738P - Impact of digital platforms on exposure to tobacco and new smoking devices: A survey approach
Presenter: Diego de Haro
Session: Poster session 23
1739P - Lung cancer mortality patterns of tobacco users in the United States: A 21-year analysis (1999-2020)
Presenter: Seif Bugazia
Session: Poster session 23
1740P - Geolocation of respiratory tract cancer and its relationship with chronic exposure to PM2.5 pollutants
Presenter: Moisés González-Escamilla
Session: Poster session 23
1741P - Are physicians aware of lung cancer screening benefits and the importance of implementing this? Data from two public hospitals in Buenos Aires province, Argentina
Presenter: Valentin Vidal
Session: Poster session 23
1742P - Gender differences in incidence trends of early-onset GI cancer: The European perspective
Presenter: Irit Ben-Aharon
Session: Poster session 23
1743P - Bridging the gender gap in oncology: GEORGiNA'S quest for equality in academic research
Presenter: Khalid El Bairi
Session: Poster session 23
1744P - Socioeconomic inequalities in the diagnosis and treatment of colon cancer: A population-based English cancer registry study
Presenter: Benjamin Pickwell-Smith
Session: Poster session 23
1745P - Why do adult patients with cancer abandon treatment in India? A nationwide qualitative study to understand the perspectives of healthcare workers
Presenter: Reshma Ayiraveetil
Session: Poster session 23
1746P - Unintended consequences: Working time directives and oncology staff implications
Presenter: Simon Barry
Session: Poster session 23